BD (NYSE:BDX) today announced the appointment of a new CFO alongside Street-beating second-quarter financial results.
Franklin Lakes, New Jersey-based BD named Vitor Roque as its new CFO, following about six months in the post in an interim capacity. Roque took over on a temporary basis when Chris DelOrefice departed in December 2025. Now, he has the permanent role.
Shares of BD ticked up 2.3% to $147.96 apiece before the market opened today.
Roque has more than 25 years at BD under his belt. Most recently, he served as SVP, finance nad corporate financial planning and analysis. During his interim CFO stint, he led the company’s global finance function, helping complete the separation of its Biosciences & Diagnostic Solutions business during the second quarter.
“This is an important moment for BD, and I’m honored to step into this role as we accelerate on our progress,” said Roque. “After more than two decades with the company, I see tremendous opportunity ahead – with a clear, well‑defined strategy to unlock significant growth and increase our impact on global healthcare. With a strong operating foundation, disciplined financial management, and focused execution, BD is well positioned to drive consistent performance, deliver durable growth and increase shareholder value creation as we continue to deliver on our Purpose of advancing the world of health.”
A look at the company’s second-quarter results
For the second quarter, BD reported losses from continuing operations (excluding the performance of the now-separated Bioscicences & Diagnostic Solutions business) of $37 million. That equals 13¢ per share on sales of $4.71 billion for the three months ended March 31, 2026.
BD recorded a bottom-line slide into the red from profits of $158 million this time a year ago on a sales increase of 5.2%.
Adjusted to exclude one-time items, earnings per share came in at $2.90. That landed 13¢ ahead of expectations on Wall Street. Sales also topped the forecasts, as experts projected $4.67 billion in revenue.
BD reported growth across segments, with Interventional leading the way, increasing revenues by 7.3%. Connected Care (4.9%), Medical Essentials (4.7%) and BioPharma Systems (2.5%) followed.
For 2026, BD maintains its revenue guidance for low single-digit plus growth. The company raised its adjusted EPS outlook from $12.35-$12.65 to $12.52-$12.72.
Commentary from BD Chair, CEO and President Tom Polen
On the company’s second-quarter performance:
“We delivered a solid second quarter, with revenue, margins and EPS all ahead of our expectations. Execution was broad-based, with more than 90% of the business delivering mid‑single‑digit growth, strong performance from our growth platforms and ongoing margin momentum from BD Excellence. Based on our first‑half performance and improved visibility into the balance of the year, we are raising our full‑year adjusted EPS guidance and reaffirming our revenue growth expectations. We remain focused on disciplined execution of our New BD strategy, including advancing our commercial and innovation initiatives across key growth platforms, expanding margins, and delivering on our capital allocation framework, all to drive sustainable long‑term shareholder value.”
On Roque’s appointment as CFO:
“Following a comprehensive search process, it was clear that Vitor is the right leader to serve as BD’s next CFO, reflecting both his capabilities and the strength of our leadership pipeline. Vitor brings an unmatched understanding of our business, a proven ability to translate strategy into performance and the discipline to drive consistent execution at scale. He has been an important leader in advancing our transformation and strengthening financial performance, and I’m confident he will help us deliver the next phase of growth and create long-term value for our shareholders and customers.”
